Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:51:09.915Z.
Calculation as of: 2026-10-06T15:51:09.915Z.
Quote observation: 2026-10-06T15:50:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7917a7cc8c7b4e75475caf5d3db61bffcb49ffeef440a300017a50834728fbad
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cytokinetics, Incorporated (CYTK) | $7.70B | N/A | N/A | N/A | N/A |
| HealthEquity, Inc. (HQY)vs › | $7.67B | 0.40 | 1.77 | 3.07 | 3.07 |
| Hinge Health, Inc. (HNGE)vs › | $7.58B | N/A | N/A | N/A | N/A |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.89B | N/A | N/A | N/A | N/A |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.37B | N/A | N/A | N/A | N/A |
| Caris Life Sciences, Inc. (CAI)vs › | $8.08B | N/A | N/A | N/A | N/A |
| Alkermes plc (ALKS)vs › | $7.08B | N/A | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.42B | N/A | N/A | N/A | N/A |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.69B | N/A | N/A | N/A | N/A |
| Immunovant, Inc. (IMVT)vs › | $6.68B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
